“While the phase 3 results of GCAptAIN did not replicate the positive outcomes observed in the phase 2 trial, we remain committed to continuing to drive scientific progress and deepening the ...

Novartis NVS announced that a late-stage study of its interleukin-17A inhibitor, Cosentyx (secukinumab), has failed to meet ...

Cosentyx missed its main goal in a Phase 3 GCA study, but showed lower steroid use. Novartis plans full review of the trial ...

Novartis (NVS) stock slips as the company's anti-inflammatory agent Cosentyx fails primary goal in a Phase 3 trial for giant ...

Dow Jones Newswires is a market-moving financial and business news source, used by wealth managers, institutional investors and fintech platforms around the world to identify trading and investing ...

Novartis said on Thursday that its Cosentyx drug had failed in a late-stage trial on adults with giant cell arteritis (GCA), ...

NAION risk is most significant within the first 12 months of beginning semaglutide, and is highest in patients with additional risk factors.

Optic nerve sheath enhancement on MRI by ophthalmologic symptoms and exam findings in affected and unaffected eyes of giant cell arteritis. Among 10 patients with ocular giant cell arteritis who had ...

Temporal arteritis: When blood vessels inflame Temporal arteritis, also known as giant cell arteritis, represents one of the more serious causes of one-sided head pain, particularly in adults over 50.

Autosomal dominant optic atrophy and cataract, also called autosomal dominant optic atrophy type 3, which causes vision impairment due to a range of problems within the eyes, including cell loss ...

The following is a summary of “Optic nerve sheath enhancement on orbital MRI in giant cell arteritis,” published in the December 2024 issue of Ophthalmology by Ephrem et al. Differentiating arteritic ...

Background Differentiating arteritic anterior ischaemic optic neuropathy (A-AION) due to giant cell arteritis (GCA) from non-arteritic anterior ischaemic optic neuropathy (NA-AION) may pose a ...